to endothelial dysfunction, vascular disease, and mortality in patients with severe CKD. Therefore, the objectives of the present study were to examine the impact of KTx on the circulating levels of ANGPTL2, to identify the determinants of ANGPTL2 after KTx, and to examine its association with vascular stiffness and mortality.
METHODS

Study design and patient population
This is an observational study involving patients with stage-5 kidney disease who were undergoing KTx. All adult patients who were offered KTx at CHU de Québec between September 2007 and October 2011 were eligible. The inclusion and exclusion criteria of these subjects have been previously reported. 10, 18 In brief, all patients were adults, with end-stage kidney disease, and were on chronic dialysis with palpable brachial, femoral, and carotid pulse so as to obtain a reliable reading of hemodynamic parameters. 10, 18 Furthermore, subjects with a graft failure in need of dialysis by 3 months post-transplantation were excluded for the analysis. The protocol was approved by the Institutional Review Board (Comité d'Éthique de la recherche du CHU de Québec-Université Laval) and the study was conducted in accordance to the Declaration of Helsinki. All patients provided informed written consent.
During this period, 212 patients received a renal transplantation, 124 patients were not approached to participate because of the lack of time or personnel to enroll patients before surgery. Therefore, 88 patients were approached, met the inclusion criteria and were enrolled. Among these, 13 patients were excluded for the following reasons: consent withdrawal (n = 5), graft failure that required dialysis 3 months after KTx (n = 4), and absence of blood samples (n = 4). The analysis was therefore performed on 75 patients undergoing a KTx ( Figure 1 ). All patients were treated with a standard immunosuppressive regimen composed of tacrolimus, mycophenolate mofetil, and corticosteroids. There were 16 living-donors KTx, 59 cadaveric donors, and 15 dual KTx. All patients underwent clinical, biochemical, hemodynamic, and pharmacological evaluations 3 months post-KTx. For survival analysis, there was no loss to followup and the vital status was assessed up to June 2016, for a median follow-up of 90 months (79-95).
Hemodynamic parameters
Hemodynamic measurements were assessed after a 15-minutes rest period in a supine position. Carotidfemoral pulse wave velocity (cf-PWV) was evaluated using Complior SP (Artech Medical, Pantin, France) as previously described. 10 Brachial blood pressure (BP) was determined with an automatic oscillometric sphygmomanometer BPM-100 (BP-Tru, Coquitlam, Canada). Central BP was determined using generalized transfer function of radial artery waveform, obtained through tonometry (Sphymocor) after calibration using brachial systolic and diastolic BP. In patients with arteriovenous fistula, all measurements were performed on the contralateral side.
Biological parameters
Serum samples were immediately centrifuged and stored at −80°C. Endothelin-1 and pentosidine were measured as previously described. 10, 18 Serum cytokines profile (IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, and TNFα) was measured by ELISA using a Ciraplex Human Cytokine 10-Plex Array (Aushon BioSystems, Billerica, MA). Serum ANGPTL2 level was measured by ELISA using a kit for human Angiopoietin-like-protein 2 (#SEB919Hu) (Cloud-Clone Corporation, Houston, TX) as previously described. 17, 19 
Statistical analysis
Data are presented as mean ± SD or median (25 th -75 th percentiles). Data that were not normally distributed were log transformed where indicated. Kruskal-Wallis was used to examine the differences in the levels of ANGPTL2 with respect to the cause of renal disease. Changes of ANGPTL2 levels after KTx were tested using Wilcoxon rank test. Independent Student t, Mann-Whitney U test, or chi square was used as appropriated to examine differences between subjects according to the median level of ANGPTL2. Determinants of ANGPTL2 were further examined using forward conditional logistic regression. Survival analysis was performed using Kaplan-Meier and Cox regression analysis. Analysis was performed using SPSS 23.
RESULTS
The baseline characteristics of the patients who underwent KTx and were dialysis-independent by the third month post-KTx are presented in Table 1 . Three months after KTx, the levels of ANGPTL2 decreased significantly from 71 ng/ ml (53-95) to 11 ng/ml (9-15) (P < 0.001), as shown in Figure 2 .
Three months after KTx, the group of patients with higher ANGPTL2 levels (>median of 11 ng/ml) were older, had a lower estimated glomerular filtration rate and a higher prevalence of diabetes and CVD (Table 2 ). In addition, among the hemodynamic parameters, cf-PWV, and central pulse pressure were higher in the group with higher ANGPTL2 levels ( Table 2 ). There was also a higher level of circulating endothelin-1 in the group with higher ANGPTL2 levels (Table 2) . Finally, lower HDL and higher TG levels were observed in patients with higher ANGPTL2 levels ( Table 2) . However, no association between circulating cytokines levels and the levels of ANGPTL2 was found ( Table 2) . We found no differences in the levels of ANGPTL2 and the cause of kidney disease at baseline (diabetes: 71 ± 6; vascular disease: 73 ± 9; others: 77 ± 5 (P = 0.897)). But there was a slightly higher level of ANGPTL2 in patients with diabetic kidney disease at 3 months post-transplant (diabetes: 16 ± 2; vascular disease: 13 ± 2; others: 12 ± 1 (P = 0.019)).
In a multiple logistic regression analysis, using a forward conditional approach, only age, estimated glomerular filtration rate, and endothelin-1 were independently associated with higher levels of ANGPTL2, whereas prevalence of CVD and diabetes were excluded from the model based on statistical criteria (Table 3 ). This association remained the same even after incorporation of cause of renal diseases into the model. Figure 3 shows a positive relationship between aortic stiffness assessed by cf-PWV and ANGPTL2 levels measured 3 months after KTx. In a linear regression analysis, ANGPTL2 was positively associated with aortic stiffness assessed by cf-PWV (standardized β = 0.280; P = 0.015) and with central pulse pressure (standardized β = 0.269; P = 0.02). Adjustment for mean BP did not affect the relationships between ANGPTL2 and aortic stiffness assessed by cf-PWV (standardized β = 0.314; P = 0.008) and central pulse pressure (standardized β = 0.290; P = 0.02). However, after adjustment for age, this relationship was no longer statistically significant (P = 0.46).
After a median follow-up of 90 months (79-95), 13 (17%) deaths occurred. Figure 4 shows that post-KTx ANGPTL2 levels above median were significantly associated with a higher mortality (P = 0.0263). In a Cox regression analysis, the hazard ratio for mortality in the group of higher ANGPTL2 was 3.9 (95% confidence interval: 1.07-14.4; P = 0.039). Because of low number of events, further adjustment was not possible. Table 4 shows the relative importance of each parameter and its relation to mortality using a univariate Cox regression analysis.
DISCUSSION
This study demonstrates for the first time that circulating levels of ANGPTL2 are extremely elevated in patients with stage-5 CKD, but KTx strongly reduces ANGPTL2 levels, indicating that the kidney is a source of ANGPTL2. Most importantly, it shows that, after KTx, ANGPTL2 levels are positively associated with aortic stiffness, central pulse pressure, renal function and mortality, independently of the inflammatory status of the patient, suggesting that ANGPTL2 may play a biological role in CKD-related CVD. ANGPTL2 is a proinflammatory circulating protein with structural homology to the angiopoietins: similarly to the latter, ANGPTL2 is composed of a N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain, but it does not bind to angiopoietins receptors Tie1 or Tie2. 20 The nature of ANGPTL2 receptors is still under debate. 21 The first report on ANGPTL2 demonstrated that ANGPLT2 may stimulate endothelial cells through a paracrine and autocrine action. 20 More recent studies revealed high concentrations of ANGPTL2 in endothelial cells and macrophages infiltrating atheromatous plaques and inducing vascular inflammation, Analysis performed using a forward conditional logistic regression analysis including age, cardiovascular disease, diabetes, age, eGFR (CKD-EPI formula), and endothelin-1. Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration. ACEi, angiotensinconverting enzyme inhibitor; ANGPTL2, angiopoietin-like 2; ARB, angiotensin receptor blockers; cf-PWV, carotid-femoral pulse wave velocity; cr-PWV, carotid-radial pulse wave velocity; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate using CKD-EPI formula; HDL, high-density lipoprotein; IFNγ, interferon gamma; IL-, interleukin-; LDL, low-density lipoprotein; MBP, mean blood pressure; PP, pulse pressure; SBP, systolic blood pressure; Smoking, past or active history; TG, triglyceride; TNFα, tumor necrosis factor alpha. Bold numbers refer to P values of <0.05. Abbreviations: cf-PWV, carotid-femoral pulse wave velocity; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate using CKD-EPI formula.
a Univariate Cox regression analysis.
endothelial dysfunction, and atherosclerosis. 11, 13, 22 In casecontrol studies, circulating ANGPTL2 was higher in patients with acute coronary syndrome and heart failure. [23] [24] [25] In diabetes, circulating ANGPTL2 is associated with increased intima-media thickness suggesting its clinical relevance for atherosclerosis. 14 This is further supported by the findings of The Hisayama Study in a general Japanese community, where circulating ANGPTL2 is associated with the risk of developing CVD and type 2 diabetes. 15, 26 Circulating levels of ANGPTL2 increase in patients with CKD 1-4 with or without type 2 diabetes. 16, 17, 26 In these studies, ANGPTL2 levels were positively correlated with albuminuria and negatively correlated with renal function estimated by estimated glomerular filtration rate. To the best of our knowledge, our study is the first to report ANGPTL2 levels in CDK-5 patients; these circulating levels (71 ng/ml, [53-95]) are extremely high when compared to those measured in patients with coronary heart disease, 19 acute coronary syndrome, 23, 25 or heart failure. 24 It is important to note that the upper threshold for normal serum ANGPTL2 concentrations has not been defined. In healthy volunteers, circulating ANGPTL2 levels range from 1 to 3 ng/ml. 19, 21, 25 In a Japanese community, serum ANGPTL2 concentrations of 2.0-3.7 ng/ml were reported, and the risk of developing CKD was significantly higher in the highest ANGPTL2 quartile (≥3.66 ng/ml). 16 In contrast to the small changes in serum ANGPTL2 reported in the literature, we previously reported high concentrations of ANGPTL2 in diabetic patients with established CKD 1-4 (ranging from 11.2 to >19.5 ng/ml). 17 It is in accordance with a Chinese group 26 that also reported high ANGPTL2 levels in diabetic patients with established CKD 1-4, ranging from 2.1 to 72.3 ng/ml. It is therefore not surprising that higher levels of ANGPTL2 were measured in patients with severe CKD 5. It has indeed been proposed that reduced kidney clearance associated with CKD could cause an increase in ANGPTL2 levels, 16 explaining the discrepancies with other diseases and previous studies. The mechanism of ANGPTL2 clearance is, however, unknown and this hypothesis remains to be validated. In addition, the patients included in the present study were on dialysis before KTx, which could be another source to increase ANGPTL2 levels: dialysis promotes inflammation, high levels of cytokines and oxidative stress, 27 all known to stimulate the expression of ANGPTL2. 28, 29 Furthermore, ANGPTL2 is a protein of ≈64 kDa, which potentially forms multimers in the circulation, making its glomerular excretion or its clearance during the dialysis likely impossible. This has never been confirmed for ANGPTL2, but angiopoeitin2, a glycoprotein with similar structure and molecular weight, is not excreted, not detectable in urine and is not eliminated by dialysis. 30, 31 Therefore, the severity of the disease and the proinflammatory environment promoting ANGPTL2 could explain the very high levels of ANGPTL2 observed in patients with CKD5 on dialysis before transplantation. Given the biological role of ANGPTL2 in atherosclerosis, 11, 13 the increased levels of ANGPTL2 in CKD could play a significant role in CKD-related endothelial dysfunction, inflammation, and CKD-related CVD. The fact that ANGPTL2 levels are significantly reduced and almost normalized after KTx suggests that the diseased kidney is a significant source of ANGPTL2. This is the first report of a beneficial effect of KTx on ANGPTL2 levels. The molecular mechanisms involved in the reduction of ANGPTL2 after KTx remain to be elucidated. In our study, in patients with ANGPTL2 >median 3 months after KTx, there was a higher level of serum endothelin-1, suggesting that ANGPTL2 is associated with endothelial dysfunction; this is in accordance with our previous report showing that ANGPTL2 promotes endothelial dysfunction in mice. 12 In addition, higher post-KTx ANGPTL2 levels were also associated with an increase in aortic stiffness as assessed by cf-PWV and by an increase in central pulse pressure; accordingly, higher post-KTx ANGPTL2 levels were associated with lower renal function. While ANGPTL2 levels have previously been associated with vascular remodelling in patients with CVD, 13,14 our study is the first report of an association between circulating ANGPTL2 and aortic stiffness, a process contributing to the development of structural changes associated with aging and cardiovascular events including renal failure. 32 Our current data linking ANGPTL2 to aortic stiffness and central pulse pressure is in agreement with our recent demonstration that levels of ANGPTL2 are positively associated with resting systolic BP. 19 Altogether, these data suggest that ANGPTL2 plays a biological role in CKD-related CVD. Unexpectedly, there was no significant association between ANGPTL2 and inflammation as measured by the extensive circulating cytokines levels, suggesting that the deleterious effects of ANGPTL2 are independent of these inflammatory mediators. Beside its proinflammatory properties, ANGPTL2 is also recognized for its profibrotic activity, supported by a recent study showing that ANGPTL2 combined with TGFβ contribute to renal fibrosis in mouse models, and are coexpressed in renal tubule and glomeruli of patients with fibrotic kidney diseases compared to less fibrotic kidneys. 33 Altogether, these data support the concept that ANGPTL2 is profibrotic in addition of its proinflammatory activity, which could contribute to renal tubule fibrosis 33 and possibly to large artery fibrosis and stiffening.
Finally, in a multivariable model, age, renal function, and endothelin-1 levels predicted post-KTx ANGPTL2 levels independently of diabetes and CVD in our patient population. ANGPTL2 levels were also associated with increased risk of overall mortality. This association between ANGPTL2 and mortality is in accordance with our previous report showing that in diabetic CKD 1-4 patients, ANGPTL2 is associated with an increased risk of cardiovascular events and death. 17 This study has several strengths as it evaluates the impact of ANGPTL2 in a well-characterized population in terms of comorbidities, hemodynamic parameters, circulating cytokine profile, and mortality. However, there are some limitations in the present study that are mainly related to a relatively small sample size. As such, the number of deaths were small and did not allow to properly study the impact of ANGPTL2 on mortality while taking into account potential confounders.
In conclusion, this is the first study to show that circulating ANGPTL2 levels improve rapidly and significantly after successful KTx. Nonetheless, post-KTx ANGPTL2 levels are associated with higher endothelin-1 levels, aortic stiffness, renal function, and mortality, suggesting that ANGPTL2 plays an active role in CVD associated with kidney disease.
